חוב לטווח קצר להון עצמי Coeptis Therapeutics (COEP)

Coeptis Therapeutics relies on high-precision delivery of biologics via secured cold chains, ensuring raw material integrity and high margins. The development of the SNAP-CAR platform for T-cell management serves as a powerful driver of capitalization. This historical price chart demonstrates a metric at the level of 0.01. High physician confidence in blood cancer treatment methods and positive clinical expectations create significant growth potential.

This ratio measures the proportion of short-term liabilities within the equity structure, allowing for an assessment of liquidity risk and the company's dependence on immediate refinancing. The trend of the short-term leverage ratio reflects the financial stability of Coeptis Therapeutics (COEP) during the implementation of robotic cell separation systems, where the balance between debt and equity determines the pace of bio-screening modernization and the speed of preclinical research.